Skip to content
DataLookout
Start free
Menu

NCT07238907

A Multi-center Retrospective Study of INO Treating B-ALL

StatusActive, Not Recruiting
PhaseNot specified
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 21 words
    • Study completion pushed from Jul 31, 2026 to Nov 30, 2026
    • Secondary endpoints: details revised at 4 of 4 entries
  2. Secondary endpoints revised (4)v2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

overall response rate
Timeframe: Till the end of the study, up to 12 months

Secondary (4)

minimal residual disease negativity rate
overall survival
Relapse-free survival
Hematological toxicity: neutropenia, thrombocytopenia, febrile neutropenia, anemia, bone marrow suppression Non hematological toxicity: SOS,TLS, peripheral edema, fever, fatigue, MODS, infection, liver dysfunction, renal dysfunction et al.

Arms and interventions

observation group

Drugs: Inotuzumab Ozogamicin

Sites

1 site in 1 country

  • Ruijin Hospital, Shanghai Jiaotong University School of MedicineShanghai, Shanghai Municipality, China